Search for: "In re: sanofi-aventis Securities Litigation" Results 21 - 24 of 24
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
23 Aug 2008, 1:23 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com]   Highlights this week included: DRM for streaming music dies a quiet death: (Electronic Frontier Foundation), (Techdirt) CAFC decides Apotex and Impax infringed AstraZeneca’s Prilosec patents: (Law360), (Patent Prospector), (Patent Docs), (GenericsWeb), CAFC upholds lower court’s decision finding USPTO was within its rights to subject a Cooper patent to… [read post]
9 May 2008, 10:30 pm
: (Afro-IP), (Managing Intellectual Property), Rwanda: Four years after AIDS drugs bill passed, first low cost meds may head to Rwanda: (GenericsWeb), US: Abbott’s first quarter lobbying tab hits $880,000: (Patent Docs), US: House Bill would expand federal drug pedigree requirements and preempt state requirements: (FDA Law Blog), US: Purchasing Canadian drugs and patent infringement: Litecubes decision: (Patently-O), US: Neuralstem seeks to reopen stayed patent case… [read post]
25 Jan 2008, 1:00 am
: (IP ThinkTank),IBM patents and defensive publishing: (Securing Innovation),Stockholm Network paper on developing nations and pharmaceutical patents: (IPcentral Weblog),Good and bad news for the IP industry if recession does bite: (IAM),Business Software Alliance: Piracy economic impact is tens of billions of dollars: (Ars Technica),IP portfolio costs - when less is more: (IP ThinkTank),IP protection: Competitive market default: (The … [read post]
8 Feb 2008, 7:00 pm
– Facebook’s contractual rights to users’ photos problematic: (Spicy IP)PharmaEuropean Commission probes pharmaceutical sector: (Philip Brooks),WHO Board sets course on IP, avian flu, tighter publication policy: (Intellectual Property Watch),India: The Competition Act, patents and over hyped drugs: (Part I - Spicy IP), (Part II – Spicy IP), (Part III – Spicy IP),Ignoring not the solution –… [read post]